<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00729690</url>
  </required_header>
  <id_info>
    <org_study_id>08021105</org_study_id>
    <nct_id>NCT00729690</nct_id>
  </id_info>
  <brief_title>Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement</brief_title>
  <official_title>Effects of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Total Knee Replacement (TKA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asokumar Buvanendran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves research. Pregabalin is a Food and Drug Administration (FDA) medication
      approved in the United States for the treatment of nerve pain related to diabetes and
      post-herpetic neuralgia &quot;shingles&quot;, and for seizures in adults. The purpose of this research
      is to study the effect of oral Pregabalin on spinal neurotransmitters in subjects undergoing
      Total Knee Replacement Surgery (TKA). TKA is associated with considerable postoperative pain
      which if unrelieved may result in prolonged hospital stay, inability to participate in
      rehabilitation programs, poor outcomes, and greater use of health-care resources. This study
      examines the effect of pregabalin administered for TKA on pain-related neurotransmitter
      concentrations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gabapentin and the related more potent compound pregabalin have been shown to reduce
      postoperative pain in animal models (1). Pregabalin given before and after surgery reduced
      opioid use following spinal fusion surgery (2). Studies have identified the alpha 2 delta
      auxiliary subunit of voltage-gated calcium channels as the molecular target of pregabalin
      (and gabapentin), although the specific spinal site of action (presynaptic, postsynaptic) is
      not known.

      Total knee arthroplasty (TKA) has proved to be a successful surgical treatment of knee joints
      affected by osteoarthritis. Currently in the United States, more than 400,000 TKAs are
      performed every year with reported success rates ranging from 85% to 90% (American Academy).
      In an aging population, the number of annual TKA procedures is expected to reach 3.48 million
      by the year 2030 (3).

      TKA is associated with considerable postoperative pain which if unrelieved may result in
      prolonged hospital stay, inability to participate in rehabilitation programs, poor outcomes,
      and greater use of health-care resources. Perioperative pregabalin improves postoperative
      outcomes after TKA (4). This study examines the effect of pregabalin administered
      perioperatively for TKA on pain-related neurotransmitter concentrations, intrathecal
      analgesic consumption and range of motion (ROM). Pregabalin effects on neurotransmitter
      concentrations may identify pathways by which α2δ binding by pregabalin reduces postoperative
      pain.

      Objectives:

      Primary Endpoint: Measure effect of pregabalin on spinal neurotransmitters after TKA
      Secondary Endpoint: Correlate changes in spinal neurotransmitters with pregabalin to
      improvements in patient outcomes after TKA (e.g. ROM).

      Other Endpoints: Suggest spinal anatomical sites of action of oral pregabalin as relates to
      neurotransmitter modulation and pain.

      Methods:

      Patient selection After approval of the Institutional Review Board of Rush University Medical
      Center, Chicago, Illinois, USA, 48 patients scheduled to undergo elective primary TKA by a
      single orthopedic surgeon will be contacted and assessed for study eligibility with a
      screening medical history.

      A study consent form will be sent to patients who agreed to participate in the clinical
      study. After obtaining consent, the patient will be allocated a study number and the study
      drug dispensed to each participant. Using a random number table, patients will be allocated
      to one of three groups, without stratification by demographic characteristics:

      Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior
      to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.

      Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour
      prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.

      Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as
      Groups 1 and 2.

      The 12 hour dosing interval was based on our pharmacokinetic study showing that after a 300
      mg oral pregabalin dose, cerebrospinal fluid (CSF) pregabalin concentration reaches its peak
      at 8 h or later (5). Study drug administration on the day of surgery was timed to precede
      surgical incision by 60 +/- 30 minutes.

      The physicians and nurses managing the patient during surgery and in the recovery room, the
      personnel involved with postoperative pain assessment and management of the intrathecal
      infusion, and the study patients will be blinded to group assignments. Treatment assignment
      codes will not be available to the investigators until all patients completed the study. A
      global pain score using the visual analogue scale (VAS) with 0 corresponding to &quot;no pain&quot; and
      10 to &quot;the worst imaginable pain&quot; for the patient will be obtained before surgery. In the
      operating room, patients will be sedated with midazolam (0.05 mg/kg titrated to effect) and
      an intrathecal catheter placed in the sitting position, at the L3-4 or L4-5 vertebral level
      to deliver spinal anesthesia with bupivacaine 0.5%, (7.5 mg) and fentanyl 25mcg. Subjects
      will be maintained at normothermia in the operating room. A sensory analgesic level of T10
      will be obtained prior to commencement of surgery. At completion of surgery an intrathecal
      infusion of fentanyl 0.5 mcg/ml and bupivacaine 0.1 mg/ml will be initiated using a
      continuous basal infusion with superimposed patient controlled intrathecal analgesia (PCIA)
      bolus doses. Initial infusion rates will be 4 ml/h basal intrathecal infusion plus PCIA of 1
      ml q 12 min with a 4-hour lockout of 40 ml. The patients will be instructed prior to surgery
      to use PCIA mode at their discretion to maintain the VAS pain score &lt;4, following a
      previously applied protocol (6). A standardized surgical technique will be used in all
      subjects.

      The intrathecal catheter will be left in place for 32 h postoperatively to provide analgesia,
      and lumbar CSF (0.5 ml) will be withdrawn (0.5 mL) at 2, 4, 8, 12, 24, and 32 h after the
      initial oral dose. CSF will be frozen at -80 Centigrade (C) for subsequent assay of
      neurotransmitter levels. Even though CSF pregabalin does not reach its peak concentration
      until at least 8 h after an oral dose, earlier time points are important because:

        1. Even at 2 h post-dose the CSF pregabalin concentration is already 29% of peak value, and
           may cause changes in neurotransmitter levels, compared to placebo.

        2. CSF inflammatory mediators, such as Interleukin-6 (IL-6), increase as early as 3 h after
           start of surgery after total hip arthroplasty (7), and so it can be expected that
           neurotransmitter levels will also show early changes due to the TKA surgery alone. Any
           characterization of pregabalin effects on neurotransmitters after surgery needs to also
           measure these early changes in neurotransmitter levels, since later time points (e.g. 24
           h) are not independent of events occurring earlier.

      Adverse Events:

      Any adverse events will be noted and reported.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NRS Pain Score AUC (NRS*hr) - 1st 24 Hours</measure>
    <time_frame>24 hours</time_frame>
    <description>Numerical Response scale NRS(0-10) Pain scores were collected every 4 hours after the initial dose and the Area Under the Curve (AUC) calculated. Calculated for the 1st 24 hours after initial dose (0-24hr). AUC measured in NRS pain score points per hour (NRS*hr). Larger AUC values indicate higher levels of reported pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NRS Pain Score AUC (NRS*hr) - 1st 12 Hours</measure>
    <time_frame>12 hours Post dose</time_frame>
    <description>Numerical Response scale NRS(0-10) Pain scores were collected every 4 hours after the initial dose and the Area Under the Curve (AUC) calculated. Calculated for the 1st 12 hours after initial dose (0-12hr). AUC measured in NRS pain score points per hour (NRS*hr). Larger AUC values indicate higher levels of reported pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Active Knee Flexion</measure>
    <time_frame>PostOp day 2</time_frame>
    <description>The degree of active knee flexion (ROM) tolerated by the patient will be assessed at days 1 and 2 post-surgery. Active flexion is the unassisted moment of the joint by the subject. On postoperative (PostOp) day 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Passive Knee Flexion</measure>
    <time_frame>PostOp day 2</time_frame>
    <description>Passive flexion is the moment of the joint with the assistance of a clinician (The clinician or therapist physically hold and moves the knee through it's range of motion).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>PAIN</condition>
  <arm_group>
    <arm_group_label>1 Multi-Dose Pregabalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 single-dose pregabalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.
Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.
Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.</description>
    <arm_group_label>1 Multi-Dose Pregabalin</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.</description>
    <arm_group_label>2 single-dose pregabalin</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.</description>
    <arm_group_label>3 Placebo</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of osteoarthritis

          -  Subjects who can understand and communicate in English

        Exclusion Criteria:

          -  Younger than 55 years or older than 75 years.

          -  American Society of Anesthesiologists physical status IV

          -  Prior use of pregabalin or gabapentin will not be an exclusionary criterion; however
             patients will have been withdrawn from these medications at least 14 days before
             surgery

          -  Patients who are currently enrolled in another investigational study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asokumar Buvanendran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffery S Kroin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Buvanendran A, Kroin JS, Della Valle CJ, Moric M, Tuman KJ. Cerebrospinal fluid neurotransmitter changes during the perioperative period in patients undergoing total knee replacement: a randomized trial. Anesth Analg. 2012 Feb;114(2):434-41. doi: 10.1213/ANE.0b013e31823dc5fb. Epub 2011 Dec 9.</citation>
    <PMID>22156332</PMID>
  </results_reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2008</study_first_submitted>
  <study_first_submitted_qc>August 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2008</study_first_posted>
  <results_first_submitted>October 18, 2012</results_first_submitted>
  <results_first_submitted_qc>November 20, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2012</results_first_posted>
  <last_update_submitted>November 20, 2012</last_update_submitted>
  <last_update_submitted_qc>November 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rush University Medical Center</investigator_affiliation>
    <investigator_full_name>Asokumar Buvanendran</investigator_full_name>
    <investigator_title>Attending Physician</investigator_title>
  </responsible_party>
  <keyword>Pregabalin</keyword>
  <keyword>CSF</keyword>
  <keyword>Neurotransmitter</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Neurotransmitter Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Forty-eight patients scheduled to undergo elective primary Total Knee Replacement (TKR) for osteoarthritis by 2 orthopedic surgeons were recruited at the Rush University Medical Center (Chicago, Illinois).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1 Multi-Dose Pregabalin</title>
          <description>Multi-dose pregabalin: patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.</description>
        </group>
        <group group_id="P2">
          <title>2 Single-dose Pregabalin</title>
          <description>Single dose pregabalin: patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.</description>
        </group>
        <group group_id="P3">
          <title>3 Placebo</title>
          <description>Placebo: patients receive matching placebo at the same 3 time points as Groups 1 and 2 (orally 1 hour prior to surgery and then repeat doses at 12 and 24 hours after initial dose.)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>IT Catheter Malfunction</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 Multi-Dose Pregabalin</title>
          <description>Multi-dose pregabalin: patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.</description>
        </group>
        <group group_id="B2">
          <title>2 Single-dose Pregabalin</title>
          <description>Single dose pregabalin: patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.</description>
        </group>
        <group group_id="B3">
          <title>3 Placebo</title>
          <description>Placebo: patients receive matching placebo at the same 3 time points as Groups 1 and 2 (orally 1 hour prior to surgery and then repeat doses at 12 and 24 hours after initial dose.)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.9" spread="6.4"/>
                    <measurement group_id="B2" value="64.8" spread="4.4"/>
                    <measurement group_id="B3" value="66.4" spread="4.5"/>
                    <measurement group_id="B4" value="66.1" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>NRS Pain Score AUC (NRS*hr) - 1st 24 Hours</title>
        <description>Numerical Response scale NRS(0-10) Pain scores were collected every 4 hours after the initial dose and the Area Under the Curve (AUC) calculated. Calculated for the 1st 24 hours after initial dose (0-24hr). AUC measured in NRS pain score points per hour (NRS*hr). Larger AUC values indicate higher levels of reported pain.</description>
        <time_frame>24 hours</time_frame>
        <population>All Completed Patients were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Multi-Dose Pregabalin</title>
            <description>Multi-dose pregabalin: patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.</description>
          </group>
          <group group_id="O2">
            <title>2 Single-dose Pregabalin</title>
            <description>Single dose pregabalin: patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.</description>
          </group>
          <group group_id="O3">
            <title>3 Placebo</title>
            <description>Placebo: patients receive matching placebo at the same 3 time points as Groups 1 and 2 (orally 1 hour prior to surgery and then repeat doses at 12 and 24 hours after initial dose.)</description>
          </group>
        </group_list>
        <measure>
          <title>NRS Pain Score AUC (NRS*hr) - 1st 24 Hours</title>
          <description>Numerical Response scale NRS(0-10) Pain scores were collected every 4 hours after the initial dose and the Area Under the Curve (AUC) calculated. Calculated for the 1st 24 hours after initial dose (0-24hr). AUC measured in NRS pain score points per hour (NRS*hr). Larger AUC values indicate higher levels of reported pain.</description>
          <population>All Completed Patients were included in the analysis.</population>
          <units>Area (NRS*hr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.4" spread="34.4"/>
                    <measurement group_id="O2" value="59.6" spread="31.1"/>
                    <measurement group_id="O3" value="73.4" spread="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For 1st 24 hours NRS AUC Pain scores</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4742</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Active Knee Flexion</title>
        <description>The degree of active knee flexion (ROM) tolerated by the patient will be assessed at days 1 and 2 post-surgery. Active flexion is the unassisted moment of the joint by the subject. On postoperative (PostOp) day 2</description>
        <time_frame>PostOp day 2</time_frame>
        <population>All completed patients used.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Multi-Dose Pregabalin</title>
            <description>Multi-dose pregabalin: patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.</description>
          </group>
          <group group_id="O2">
            <title>2 Single-dose Pregabalin</title>
            <description>Single dose pregabalin: patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.</description>
          </group>
          <group group_id="O3">
            <title>3 Placebo</title>
            <description>Placebo: patients receive matching placebo at the same 3 time points as Groups 1 and 2 (orally 1 hour prior to surgery and then repeat doses at 12 and 24 hours after initial dose.)</description>
          </group>
        </group_list>
        <measure>
          <title>Active Knee Flexion</title>
          <description>The degree of active knee flexion (ROM) tolerated by the patient will be assessed at days 1 and 2 post-surgery. Active flexion is the unassisted moment of the joint by the subject. On postoperative (PostOp) day 2</description>
          <population>All completed patients used.</population>
          <units>Degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.1" spread="10.6"/>
                    <measurement group_id="O2" value="80.5" spread="10.1"/>
                    <measurement group_id="O3" value="80.5" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7596</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>NRS Pain Score AUC (NRS*hr) - 1st 12 Hours</title>
        <description>Numerical Response scale NRS(0-10) Pain scores were collected every 4 hours after the initial dose and the Area Under the Curve (AUC) calculated. Calculated for the 1st 12 hours after initial dose (0-12hr). AUC measured in NRS pain score points per hour (NRS*hr). Larger AUC values indicate higher levels of reported pain.</description>
        <time_frame>12 hours Post dose</time_frame>
        <population>All Completed Patients</population>
        <group_list>
          <group group_id="O1">
            <title>1 Multi-Dose Pregabalin</title>
            <description>Multi-dose pregabalin: patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.</description>
          </group>
          <group group_id="O2">
            <title>2 Single-dose Pregabalin</title>
            <description>Single dose pregabalin: patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.</description>
          </group>
          <group group_id="O3">
            <title>3 Placebo</title>
            <description>Placebo: patients receive matching placebo at the same 3 time points as Groups 1 and 2 (orally 1 hour prior to surgery and then repeat doses at 12 and 24 hours after initial dose.)</description>
          </group>
        </group_list>
        <measure>
          <title>NRS Pain Score AUC (NRS*hr) - 1st 12 Hours</title>
          <description>Numerical Response scale NRS(0-10) Pain scores were collected every 4 hours after the initial dose and the Area Under the Curve (AUC) calculated. Calculated for the 1st 12 hours after initial dose (0-12hr). AUC measured in NRS pain score points per hour (NRS*hr). Larger AUC values indicate higher levels of reported pain.</description>
          <population>All Completed Patients</population>
          <units>Area (NRS*hr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" spread="15.6"/>
                    <measurement group_id="O2" value="22.7" spread="16.9"/>
                    <measurement group_id="O3" value="27.7" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4321</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Passive Knee Flexion</title>
        <description>Passive flexion is the moment of the joint with the assistance of a clinician (The clinician or therapist physically hold and moves the knee through it's range of motion).</description>
        <time_frame>PostOp day 2</time_frame>
        <population>All Completed Patients were used</population>
        <group_list>
          <group group_id="O1">
            <title>1 Multi-Dose Pregabalin</title>
            <description>Multi-dose pregabalin: patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.</description>
          </group>
          <group group_id="O2">
            <title>2 Single-dose Pregabalin</title>
            <description>Single dose pregabalin: patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.</description>
          </group>
          <group group_id="O3">
            <title>3 Placebo</title>
            <description>Placebo: patients receive matching placebo at the same 3 time points as Groups 1 and 2 (orally 1 hour prior to surgery and then repeat doses at 12 and 24 hours after initial dose.)</description>
          </group>
        </group_list>
        <measure>
          <title>Passive Knee Flexion</title>
          <description>Passive flexion is the moment of the joint with the assistance of a clinician (The clinician or therapist physically hold and moves the knee through it's range of motion).</description>
          <population>All Completed Patients were used</population>
          <units>Degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.5" spread="15.3"/>
                    <measurement group_id="O2" value="88.2" spread="9.44"/>
                    <measurement group_id="O3" value="87.1" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9361</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1 Multi-Dose Pregabalin</title>
          <description>Multi-dose pregabalin: patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.</description>
        </group>
        <group group_id="E2">
          <title>2 Single-dose Pregabalin</title>
          <description>Single dose pregabalin: patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.</description>
        </group>
        <group group_id="E3">
          <title>3 Placebo</title>
          <description>Placebo: patients receive matching placebo at the same 3 time points as Groups 1 and 2 (orally 1 hour prior to surgery and then repeat doses at 12 and 24 hours after initial dose.)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Asokumar Buvanendran</name_or_title>
      <organization>Rush University</organization>
      <phone>(312) 942-3685</phone>
      <email>asokumar@aol.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

